- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02517957
Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research
August 6, 2015 updated by: Shanghai Yueyang Integrated Medicine Hospital
On the basis of Xiashi skin surgery clinical experience, this project adopts the multicenter, randomized, double-blind, controlled trial of design type.
Objective, normative evaluation of traditional Chinese medicine cool blood latent town effectiveness of therapeutic regimen in the treatment of eczema, security, and control of the relapse of situation, provide high-level evidence-based basis for traditional Chinese medicine treatment of eczema, aims to form suitable for popularization and application of traditional Chinese medicine in the treatment of eczema.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
342
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Li Bin, director
- Phone Number: 0086-021-65162629
- Email: 18930568129@163.com
Study Contact Backup
- Name: Li Fulun, researcher
- Phone Number: 0086-021-65162629
- Email: drlifulun@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- accord with standard of syndrome differentiation of traditional Chinese medicine (blood hot sheng) and western medicine diagnostic criteria (subacute eczema);
- age between 18-65 years old, gender, ethnic unlimited;
- agreed to participate in clinical trials can observe and cooperate with the visitor on schedule;
- volunteered for this study and obtain informed consent will be;
- lesion area of about 5-30% of surface area (BSA) were (containing 3% and 3%, palm measurement method)
- IGA scale of 1 to 3 points (including);
- her lesions mainly located in the trunk and limbs (or);
- Women HCG negative;
Exclusion Criteria:
- known to the study of drug allergy to any of the components;
- previous or current with any may affect the results of systemic disease, or other activity of skin diseases (such as: psoriasis);
- has a liver and kidney function is not complete, liver damage of ALT and AST > 1.5 times the upper limit of normal, renal BUN > 1.5 times the upper limit of normal or creatinine > 1.5 times the upper limit of normal value;
- QTcB or QTcF acuity 450 milliseconds. For subjects QTc acuity bundle branch block 480 milliseconds.
- prior or current with clinical significance of cardiovascular, lung disease, gastrointestinal tract, liver, kidney, blood, nerve abnormalities or mental disease;
- breast-feeding or plan to pregnant women during test;
- skin area score > 30%;
- eosinophil count score > 10%
- for nearly two weeks taking corticosteroids or a week, both inside and outside with corticosteroid preparation;
- three months received study medication or other participated in other clinical subjects;
- for any reason cannot cooperate research, for example: how language understanding, not to research centers, etc.;
- Researchers believe can bring obvious risk patients or confuse the results of the study, which should rule out other conditions or disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Qinzhuliangxue Keli
Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
|
Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks.
Pure dry area or no skin itching area should not be applied.
Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
|
Active Comparator: loratadine tablets
Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
|
Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks.
Pure dry area or no skin itching area should not be applied.
Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
|
Active Comparator: Qinzhuliangxue and loratadine
Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
|
Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks.
Pure dry area or no skin itching area should not be applied.
Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in the Eczema Area and Severity Index (EASI) score
Time Frame: Baseline and up to week 4 of the follow up phase
|
Baseline and up to week 4 of the follow up phase
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dermatology life quality index (DLQI)
Time Frame: Baseline and up to week 4 of the follow up phase
|
Baseline and up to week 4 of the follow up phase
|
Change in Itching degree score
Time Frame: Baseline and up to week 4 of the follow up phase
|
Baseline and up to week 4 of the follow up phase
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (Anticipated)
August 1, 2017
Study Registration Dates
First Submitted
August 5, 2015
First Submitted That Met QC Criteria
August 6, 2015
First Posted (Estimate)
August 7, 2015
Study Record Updates
Last Update Posted (Estimate)
August 7, 2015
Last Update Submitted That Met QC Criteria
August 6, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14401970200
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
-
BayerCompleted
-
Cosmetique Active InternationalCompleted
Clinical Trials on Furoic acid loperamide hydrochloride cream
-
University Hospital Southampton NHS Foundation...University of SouthamptonWithdrawn
-
Xian-Janssen Pharmaceutical Ltd.Completed
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsWithdrawnChemotherapy-related DiarrheaChina
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted
-
Betta Pharmaceuticals Co., Ltd.Quintiles, Inc.Completed
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...CompletedDiarrhea | Colorectal CancerUnited States
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdTerminatedMild to Moderate PsoriasisChina
-
Spectrum Pharmaceuticals, IncTerminatedBreast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome MultiformeUnited States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted